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Influenza is a leading cause of morbidity and mortality worldwide, with vaccines and antiviral drugs
having limited efficacy thus far. Two recent studies in Cell apply lipidomics approaches to identify
bioactive lipid mediators influencing host inflammation, viral replication, and disease progression.Among viral respiratory pathogens, influ-
enza virus causes the highest numbers
of hospitalizations and deaths in humans.
Not only are seasonal influenza viruses
responsible for up to half a million deaths
worldwide, but these numbers can sig-Figure 1. Use of Lipidomics for the Identification of Therapeutic
Compounds and Biomarkers during Influenza Virus Infection
During influenza virus infection, lipid mediators are generated in the respiratory
tract that promote both pro- and anti-inflammatory responses. Exacerbated
inflammation and high viral replication result in severe disease. Mass spec-
trometry techniques can be used to determine global changes in levels of lipid
metabolites (lipidomics) associated with severe infection and inflammation.
These studies might provide novel biomarkers of pulmonary disease.
Phenotypic characterization of lipid metabolites to determine their impact in
viral replication and in inflammation could identify novel compounds with
direct antiviral activity and anti-inflammatory properties.nificantly increase during
pandemic years that occur
every 10–50 years. Available
vaccines only protect against
antigenically related strains
and have limited efficacy,
especially in the elderly, a
population at higher risk of
severe influenza. There are
limited choices of drugs for
the treatment of severe influ-
enza, and these drugs can
easily generate resistance,
as is the case with the viral
neuraminidase inhibitor osel-
tamivir. A promising approach
for the discovery of com-
pounds for the treatment of
influenza virus infections is
targeting host factors that
regulate viral replication and/
or disease. In this respect,
genomics and proteomics
studies have given us a
plethora of information on
host genes and proteins
whose regulation is associ-
ated with viral infection and
pathogenesis (Korth et al.,
2012). In addition, siRNA
screens have provided us
with a list of host genes
required for optimal influenza22 Cell 154, July 3, 2013 ª2013 Elsevier Inc.virus replication as well as restricting viral
replication (Shaw, 2011). Among host
factors involved in viral replication and/or
in pathogenesis, it is likely that some of
them can be targeted for the treatment
of influenza without significant sideeffects. However, very limited information
has been available until now with respect
to host factors different than coding
genes and proteins involved in influenza
disease. The recent studies in Cell from
Morita et al. (2013) and Tam et al. (Tamet al., 2013, this issue) provide
a comprehensive analysis of
host lipid factors regulated
during influenza virus infec-
tion that have an impact in
viral replication, inflammation,
and disease. Together, they
point toward possible new
treatment modalities based
on key bioactive lipids
involved in viral pathogenesis.
Morita et al. (2013)
screened lipid metabolites
for their impact in influenza
virus replication in human
respiratory cells. Among the
identified compounds affect-
ing virus replication, 10S
17S-dihydroxydocosahexae-
noic acid, also known as
protectin D1 (PD1), was found
to be a potent inhibitor.
Mechanistically, PD1 inter-
feres with binding of specific
host nuclear export factors
to influenza virus RNAs,
preventing viral RNA export
from the nucleus to the
cytoplasm. The authors also
conducted a comprehensive
analysis of changes in endo-
genous lipid mediators in
lungs during infection with
influenza virus in amousemodel. Interest-
ingly, PD1 levels were reduced during
infection, and the levels of reduction
correlated with virulence and disease.
Importantly, exogenous administration
of PD1 ameliorated lung function during
infection, reduced viral titers, and
increased survival. Consistent with these
data, ablation of the host enzyme 12/15-
lipoxygenase (12/15-LOX) responsible
for PD1 synthesis increased viral replica-
tion and disease.
Tam et al. (2013) also conducted a
comprehensive analysis of lipidmediators
during influenza virus infection in mouse
lungs, comparing two viruses of high
and low virulence. This analysis was
integrated with data on cytokine and
chemokine profiles, virus replication, and
transcriptomics. Interestingly, the authors
also identified lipid metabolites derived
from the 12/15-LOX pathway as differen-
tially regulated by infection according
to virulence. In the mouse, 12/15-LOX
derived metabolites were elevated during
resolution of infection with the less-viru-
lent virus. Intriguingly, levels of 12-LOX
generated metabolites also correlated
with increasing clinical symptoms in nasalwashes from influenza-virus-infected
humans. Moreover, the ratios of two other
lipid metabolites, the proinflammatory
9 HODE and the anti-inflammatory 13
HODE, were found to be predictive of
the level of inflammation, at least in the
mouse model.
Although PD1 levels were not detected
in the study by Tam et al., data from both
studies are consistent with a protective
role of 12/15 LOX-derived metabolites.
More detailed studies will be needed in
humans to validate the use of these
metabolites for the treatment of influenza.
However, the identification of lipid media-
tors that directly inhibit virus replication
while at the same time promoting resolu-
tion of inflammation due to their anti-
inflammatory properties provides the
basis for an interesting new concept for
the treatment of influenza. Other immuno-
regulatory molecules might indirectly
increase viral replication by inhibiting
antiviral inflammatory effectors, and a
right balance between beneficial effects
related to their anti-inflammatory pro-
perties and detrimental effects due to
potential increased viral replication during
reduced inflammation might be difficultCto achieve. By combining direct antiviral
activity with anti-inflammatory properties,
bioactive lipid mediators such as PD1 are
attractive candidates for the development
of new drugs for the treatment of influenza
and perhaps of other viral diseases
characterized by high viral replication in
the context of exacerbated proinflam-
matory responses (Figure 1). Because
this strategy targets host factors involved
in viral replication rather than viral
proteins, it is unlikely to be easily over-
come by the selection of resistant mutant
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Large-scale screens to identify protein interactions typically underperformwith eukaryotic extracel-
lular proteins. In this issue, O¨zkan et al. report development of a high-throughput assay designed
specifically for extracellular proteins that uncovers a wealth of new interactions among three pro-
tein superfamilies in Drosophila and sets the stage for more extensive screens.The metazoan genome sequences that
began appearing in the late 1990s
spawned an ‘‘omics’’ era in which large
arrays of gene products could be
screened for function in an automated,high-throughput fashion. Yeast two-
hybrid and affinity purification mass-
spectrometric analyses proved particu-
larly amenable to large-scale analyses
of protein-protein interactions, and manyinteraction networks, known as interac-
tomes, have been reported (Braun et al.,
2009; Guruharsha et al., 2011; Miller
et al., 2005; Yu et al., 2008). Extracellular
and transmembrane proteins turn out toell 154, July 3, 2013 ª2013 Elsevier Inc. 23
